Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Shaperon's Free Cash Flow for the
three
months ended in Mar. 2026 was ₩-3,170.5 Mil. Shaperon's Revenue for the
three
months ended in Mar. 2026 was ₩65.4 Mil. Therefore, Shaperon's FCF Margin % for the quarter that ended in Mar. 2026 was -4,847.81%.
The historical rank and industry rank for Shaperon's FCF Margin % or its related term are showing as below:
XKRX:378800'
s FCF Margin % Range Over the Past 10 Years
Min: -97724.71 Med: -6543.43 Max: -406.95
Current: -4927.85
During the past 7 years, the highest FCF Margin % of Shaperon was -406.95%. The lowest was -97724.71%. And the median was -6543.43%.
XKRX:378800's FCF Margin % is ranked worse than 90.63% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs XKRX:378800: -4927.85
Shaperon FCF Margin % Related Terms
Shaperon FCF Margin % Historical Data
* Premium members only.
The historical data trend for Shaperon's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKRX:378800 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Shaperon's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shaperon FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shaperon's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Shaperon's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shaperon (XKRX:378800) has a FCF Margin % of -4,847.81% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shaperon and its competitors. According to the industry distribution chart, Shaperon ranks #861 out of 950 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Shaperon's FCF Margin % too high?
Shaperon's current FCF Margin % is -4,847.81%. Based on the distribution chart, Shaperon ranks #861 out of 950 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Shaperon has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shaperon's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shaperon ranks #861 out of 950 companies for FCF Margin %. This places Shaperon in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Shaperon and its competitors. Shaperon's current FCF Margin % is -4,847.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shaperon stock overvalued right now?
Based on GuruFocus' analysis, Shaperon (XKRX:378800) is currently considered Possible Value Trap. The stock's GF Value™ is ₩4,387.74, compared to a current price of ₩514.00 — trading 88.3% below its estimated fair value. The current FCF Margin % is -4,847.81%. Shaperon's overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Shaperon (XKRX:378800), the current FCF Margin % is -4,847.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shaperon (XKRX:378800) Overvalued in 2026?
Based on GuruFocus' analysis, Shaperon stock appears to be undervalued.
The current stock price of ₩514.00 is trading 88.3% below its estimated GF Value™ of ₩4,387.74.
GuruFocus considers Shaperon to be Possible Value Trap.
Key valuation signals for XKRX:378800:
FCF Margin %: -4,847.81%
GF Value™: ₩4,387.74 vs. price of ₩514.00 (88.3% below fair value)
No single metric tells the full story. See the XKRX:378800 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shaperon Inc is a developer of innovative inflammasome inhibitors and nanobody therapeutics intended to develop novel treatments for various chronic inflammatory diseases, including atopic dermatitis, systemic inflammatory response syndrome, neuroinflammatory diseases, and chronic inflammation. It offers a range of drug candidates, including a gel-type atopic dermatitis drug for use in the treatment of systemic inflammatory response syndrome, neuroinflammatory diseases and for treating chronic inflammation. The company also provides immunotherapeutic products and a single-domain neutralizing antibody, enabling clients to improve patient's quality of life by developing safe and efficacious drugs and immunotherapies.
31GF Score
Get the complete analysis for XKRX:378800
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:378800 has been successfully added to your 
